Advertisement

Journal of Neuro-Oncology

, Volume 71, Issue 2, pp 161–168 | Cite as

Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma

  • Bich-Ngoc-Thanh Tang
  • Niloufar Sadeghi
  • Fabrice Branle
  • Olivier De Witte
  • David Wikler
  • Serge Goldman
Clinical Study

Abstract

11C-Methionine (MET) is a useful positron emission tomography (PET) tracer for the evaluation of low-grade gliomas. Among these tumors, a high percentage of low-grade oligodendrogliomas (ODG) are sensitive to chemotherapy with procarbazine, CCNU, and vincristine (PCV). We aimed at: (1) objectively assessing ODG response to PCV by a metabolic index (the Activity Volume Index or AVI) generated from an automated semi-quantification of PET with MET (PET-MET); (2) comparing AVI and quantitative magnetic resonance imaging (MRI) measurements of response to PCV.

Methods: seven patients with ODG were followed for a period of 19.9±6.6months after the completion of PCV chemotherapy. Regions of interest (ROI) were generated by covering all voxels with count values above a threshold level set at 120% of the mean cerebellar activity. On each slice, ROI volume and mean count values were calculated. AVI was calculated as the sum over all ROI of tumor volume×(tumor mean count/cerebellum count). Tumor volume measurements on MRI, were based on signal abnormalities visually detected on fluid-attenuated inversion recovery (FLAIR) sequences.

Results: PCV therapy was associated with a drastic decrease in AVI (mean±SD, cm3): AVI post-PCV=0.80±1.45 vs. AVI prior PCV=12.94±11.46 (P=0.03). Likewise, we observed a decrease in tumor volume estimated from the FLAIR signal (31.37±11.99 post-PCV vs. 67.95±39.96 prior PCV, P=0.03) although AVI decrease after PCV was significantly more pronounced (P=0.015).

Conclusion: This study, based on limited number of patients and follow-up period indicates that AVI may be a sensitive and observer-independent method applicable to the assessment of ODG responsiveness to PCV treatment and may offer a major added value to both clinical assessment and MRI evaluation of chemotherapeutic outcomes.

Keywords

11C-methionine oligodendrogliomas PCV chemotherapy positron emission tomography 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Stieber, VW 2001Low-grade gliomasCurr Treat Options Oncol2495506Google Scholar
  2. Cairncross, JG, Macdonald, DR 1991Chemotherapy for oligodendroglioma. Progress reportArch Neurol48225227Google Scholar
  3. Glass, J, Hochberg, FH, Gruber, ML, Louis, DN, Smith, D, Rattner, B 1992The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapyJ Neurosurg76741745PubMedGoogle Scholar
  4. Mason, WP, Krol, GS, DeAngelis, LM 1996Low-grade oligodendroglioma responds to chemotherapyNeurology46203207Google Scholar
  5. Bent, MJ, Kros, JM, Heimans, JJ, Pronk, LC, Groeningen, CJ, Krouwer, HG, Taphoorn, MJ, Zonnenberg, BA, Tijssen, CC, Twijnstra, A, Punt, CJ, Boogerd, W 1998Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology GroupNeurology5111401145PubMedGoogle Scholar
  6. Buckner, JC, Gesme, D, O’Fallon, JR, Hammack, JE, Stafford, S, Brown, PD, Hawkins, R, Scheithauer, BW, Erickson, BJ, Levitt, R, Shaw, EG, Jenkins, R 2003Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalitiesJ Clin Oncol21251255CrossRefPubMedGoogle Scholar
  7. Diabira, S, Rousselet, MC, Gamelin, E, Soulier, P, Jadaud, E, Menei, P 2001PCV chemotherapy for oligodendroglioma: response analyzed on T2 weighted-MRIJ Neurooncol554550Google Scholar
  8. Daumas-Duport, C, Varlet, P, Tucker, ML, Beuvon, F, Cervera, P, Chodkiewicz, JP 1997Oligodendrogliomas. Part I: Patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 casesJ Neurooncol343759Google Scholar
  9. Scott, JN, Brasher, PM, Sevick, RJ, Rewcastle, NB, Forsyth, PA 2002How often are nonenhancing supratentorial gliomas malignant. A population studyNeurology59947949PubMedGoogle Scholar
  10. Kelly, PJ 1993Computed tomography and histologic limits in glial neoplasms: tumor types and selection for volumetric resectionSurg Neurol39458465Google Scholar
  11. Herholz, K, Holzer, T, Bauer, B, Schroder, R, Voges, J, Ernestus, RI, Mendoza, G, Weber-Luxenburger, G, Lottgen, J, Thiel, A, Wienhard, K, Heiss, WD 199811C-methionine PET for differential diagnosis of low-grade gliomasNeurology5013161322PubMedGoogle Scholar
  12. Ericson, K, Lilja, A, Bergstrom, M, Collins, VP, Eriksson, L, Ehrin, E, Holst, H, Lundqvist, H, Langsrom, BB, Mosskin, M 1985Positron emission tomography with ([11C]methyl)-L-methionine, [11C]D-glucose, and [68Ga]EDTA in supratentorial tumorsJ Comput Assist Tomogr9683689Google Scholar
  13. Ogawa, T, Inugami, A, Hatazawa, J, Kanno, I, Murakami, M, Yasui, N, Mineura, K, Uemura, K 1996Clinical positron emission tomography for brain tumors: comparison of fludeoxyglucose F 18 and L-methyl-11C-methionineAm J Neuroradiol17345353PubMedGoogle Scholar
  14. Derlon, JM, Petit-Taboue, MC, Chapon, F, Beaudouin, V, Noel, MH, Creveuil, C, Courtheoux, P, Houtteville, JP 1997The in vivo metabolic pattern of low-grade brain gliomas: a positron emission tomographic study using 18F-fluorodeoxyglucose and 11C-L-methylmethionineNeurosurgery40276287discussion 287–288PubMedGoogle Scholar
  15. Goldman, S, Levivier, M, Pirotte, B, Brucher, JM, Wikler, D, Damhaut, P, Dethy, S, Brotchi, J, Hildebrand, J 1997Regional methionine and glucose uptake in high-grade gliomas: a comparative study on PET-guided stereotactic biopsyJ Nucl Med3814591462PubMedGoogle Scholar
  16. Massager, N 2002[Usefulness of PET scan guidance in stereotaxic radioneurosurgery using a gamma knife]Bull Mem Acad R Med Belg157355362discussion 363–369Google Scholar
  17. Witte, O, Goldberg, I, Wikler, D, Rorive, S, Damhaut, P, Monclus, M, Salmon, I, Brotchi, J, Goldman, S 2001Positron emission tomography with injection of methionine as a prognostic factor in gliomaJ Neurosurg95746750PubMedGoogle Scholar
  18. Bustany, P, Chatel, M, Derlon, JM, Darcel, F, Sgouropoulos, P, Soussaline, F, Syrota, A 1986Brain tumor protein synthesis and histological grades: a study by positron emission tomography (PET) with C11-L-MethionineJ Neurooncol3397404Google Scholar
  19. Voges, J, Herholz, K, Holzer, T, Wurker, M, Bauer, B, Pietrzyk, U, Treuer, H, Schroder, R, Sturm, V, Heiss, WD 199711C-methionine and 18F-2-fluorodeoxyglucose positron emission tomography: a tool for diagnosis of cerebral glioma and monitoring after brachytherapy with 125I seedsStereotact Funct Neurosurg69129135PubMedGoogle Scholar
  20. Kaschten, B, Stevenaert, A, Sadzot, B, Deprez, M, Degueldre, C, Del Fiore, G, Luxen, A, Reznik, M 1998Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionineJ Nucl Med39778785PubMedGoogle Scholar
  21. Comar, D, Cartron, J, Maziere, M, Marazano, C 1976Labelling and metabolism of methionine-methyl-11 CEur J Nucl Med1114Google Scholar
  22. Bynevelt, M, Britton, J, Seymour, H, MacSweeney, E, Thomas, N, Sandhu, K 2001FLAIR imaging in the follow-up of low-grade gliomas: time to dispense with the dual-echoNeuroradiology43129133CrossRefPubMedGoogle Scholar
  23. Reifenberger, J, Reifenberger, G, Liu, L, James, CD, Wechsler, W, Collins, VP 1994Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1pAm J Pathol14511751190PubMedGoogle Scholar
  24. Hashimoto, N, Murakami, M, Takahashi, Y, Fujimoto, M, Inazawa, J, Mineura, K 2003Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1pCancer9722542261CrossRefPubMedGoogle Scholar
  25. Smith, JS, Perry, A, Borell, TJ, Lee, HK, O’Fallon, J, Hosek, SM, Kimmel, D, Yates, A, Burger, PC, Scheithauer, BW, Jenkins, RB 2000Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomasJ Clin Oncol18636645PubMedGoogle Scholar
  26. Cairncross, JG, Ueki, K, Zlatescu, MC, Lisle, DK, Finkelstein, DM, Hammond, RR, Silver, JS, Stark, PC, Macdonald, DR, Ino, Y, Ramsay, DA, Louis, DN 1998Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomasJ Natl Cancer Inst9014731479CrossRefPubMedGoogle Scholar
  27. Brismar, T, Anderson, S, Collins, VP 1995Mechanism of high K+ and Tl+ uptake in cultured human glioma cellsCell Mol Neurobiol15351360Google Scholar
  28. Roesdi, MF, Postma, TJ, Hoekstra, OS, Groeningen, CJ, Wolbers, JG, Heimans, JJ 1998Thallium-201 SPECT as response parameter for PCV chemotherapy in recurrent gliomaJ Neurooncol40251255Google Scholar
  29. Herholz, K, Kracht, LW, Heiss, WD 2003Monitoring the effect of chemotherapy in a mixed glioma by C-11-methionine PETJ Neuroimag13269271Google Scholar
  30. Levivier, M, Wikler, D, Massager, N, David, P, Devriendt, D, Lorenzoni, J, Pirotte, B, Desmedt, F, Simon, S, Goldman, S, Houtte, P, Brotchi, J 2002The integration of metabolic imaging in stereotactic procedures including radiosurgery: a reviewJ Neurosurg97542550Google Scholar
  31. Pardridge, WM 1983Brain metabolism: a perspective from the blood-brain barrierPhysiol Rev631481535Google Scholar
  32. Langen, KJ, Muhlensiepen, H, Holschbach, M, Hautzel, H, Jansen, P, Coenen, HH 2000Transport mechanisms of 3-[123I]iodo-alpha-methyl-L-tyrosine in a human glioma cell line: comparison with [3H]methyl]-L-methionineJ Nucl Med4112501255PubMedGoogle Scholar
  33. Tsuchiya, K, Mizutani, Y, Hachiya, J 1996Preliminary evaluation of fluid-attenuated inversion-recovery MR in the diagnosis of intracranial tumorsAm J Neuroradiol1710811086PubMedGoogle Scholar
  34. Essig, M, Metzner, R, Bonsanto, M, Hawighorst, H, Debus, J, Tronnier, V, Knopp, MV, Kaick, G 2001Postoperative fluid-attenuated inversion recovery MR imaging of cerebral gliomas: initial resultsEur Radiol1120042010CrossRefPubMedGoogle Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  • Bich-Ngoc-Thanh Tang
    • 1
    • 5
  • Niloufar Sadeghi
    • 2
  • Fabrice Branle
    • 3
  • Olivier De Witte
    • 4
  • David Wikler
    • 1
  • Serge Goldman
    • 1
  1. 1.Department of Nuclear Medicine and PET/Biomedical-Cyclotron UnitUniversité Libre de Bruxelles-Hôpital ErasmeBrusselsBelgium
  2. 2.Department of RadiologyUniversité Libre de Bruxelles-Hôpital ErasmeBrusselsBelgium
  3. 3.Department of OncologyUniversité Libre de Bruxelles-Hôpital ErasmeBrusselsBelgium
  4. 4.Department of NeurosurgeryUniversité Libre de Bruxelles-Hôpital ErasmeBrusselsBelgium
  5. 5.Hospital ErasmeBrusselsBelgium

Personalised recommendations